6.2.3.1.5. combined dose-escalated radiotherapy androgen-deprivation therapy. combination adt various forms rt extensively studied, extremely strong evidence use combined modality therapy several settings. marcap (individual patient data meta- analysis randomised trials cancer prostate) consortium recently conducted meta-analysis trials using individual patient data (ipd), primary endpoint mfs, validated surrogate os. trials eligible studied use prolongation adt patients receiving definitive rt, included 12 trials 10,853 patients. median follow-up 11 years. use adt clearly associated significant improvements bcr, metastatic recurrence, mfs, os. benefits adt independent rt dose, age, risk groups comparing nccn unfavourable intermediate-risk (see sections 4.2 6.2.2.3), high-risk locally-advanced disease. demonstrable benefits extension duration neoadjuvant adt . three rcts shown benefits adt independent dose escalation, use adt would compensate lower rt dose: 1.the gicor study shows better biochemical dfs high-risk patients 3d-crt radiation dose > 72 gy combined long-term adt . 2.dart01/05 gicor shows improved os high-risk patients ten years two years adjuvant adt combined high-dose rt . 3.the european organisation research treatment cancer (eortc) trial 22991 shows six months adt improves biochemical clinical dfs irrespective dose (70, 74, 78 gy) intermediate-risk low-volume high-risk localised pca patients . meta-analysis based ipd two rcts (rtog 9413 ottawa 0101) compared neoadjuvant/concomitant vs. adjuvant adt (without substratifying favourable- unfavourable intermediaterisk disease) conjunction prostate rt reported superior pfs adjuvant adt, data heterogeneity means observation hypothesis-generating . addition, canadian two-arm dose-escalated (76 gy) rct compared neoadjuvant concomitant adjuvant short-term adt 432 patients intermediate-risk pca. ten years significant difference os rt-related grade â‰¥ 3 gi gu toxicity seen . therefore regimen combination dose escalation reasonable standards.